Basilea Pharmaceutica Management
Management criteria checks 3/4
Basilea Pharmaceutica's CEO is David Veitch, appointed in Apr 2018, has a tenure of 6.08 years. total yearly compensation is CHF1.75M, comprised of 35% salary and 65% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth CHF52.56K. The average tenure of the management team and the board of directors is 6.3 years and 9.1 years respectively.
Key information
David Veitch
Chief executive officer
CHF1.7m
Total compensation
CEO salary percentage | 35.0% |
CEO tenure | 6.1yrs |
CEO ownership | 0.01% |
Management average tenure | 6.3yrs |
Board average tenure | 9.1yrs |
Recent management updates
Recent updates
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | CHF2m | CHF611k | CHF10m |
Sep 30 2023 | n/a | n/a | CHF33m |
Jun 30 2023 | n/a | n/a | CHF56m |
Mar 31 2023 | n/a | n/a | CHF34m |
Dec 31 2022 | CHF2m | CHF599k | CHF12m |
Sep 30 2022 | n/a | n/a | CHF6m |
Jun 30 2022 | n/a | n/a | CHF851k |
Mar 31 2022 | n/a | n/a | -CHF3m |
Dec 31 2021 | CHF2m | CHF594k | -CHF7m |
Sep 30 2021 | n/a | n/a | -CHF26m |
Jun 30 2021 | n/a | n/a | -CHF45m |
Mar 31 2021 | n/a | n/a | -CHF30m |
Dec 31 2020 | CHF1m | CHF589k | -CHF15m |
Sep 30 2020 | n/a | n/a | -CHF6m |
Jun 30 2020 | n/a | n/a | CHF3m |
Mar 31 2020 | n/a | n/a | -CHF10m |
Dec 31 2019 | CHF1m | CHF583k | -CHF22m |
Sep 30 2019 | n/a | n/a | -CHF23m |
Jun 30 2019 | n/a | n/a | -CHF24m |
Mar 31 2019 | n/a | n/a | -CHF28m |
Dec 31 2018 | CHF2m | CHF529k | -CHF31m |
Compensation vs Market: David's total compensation ($USD1.93M) is above average for companies of similar size in the Swiss market ($USD1.16M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Veitch (58 yo)
6.1yrs
Tenure
CHF1,745,679
Compensation
Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 6.1yrs | CHF1.75m | 0.011% CHF 52.6k | |
Chief Financial Officer | 5.1yrs | no data | 0.0042% CHF 20.2k | |
Chief Technology Officer | 6yrs | no data | no data | |
Chief Scientific Officer | 15.3yrs | no data | 0.0042% CHF 20.2k | |
Chief Medical Officer | 6.3yrs | no data | no data | |
Head of Corporate Communications & Investor Relations | no data | no data | no data | |
General Counsel & Corporate Secretary | 6.8yrs | no data | no data | |
Head of Corporate Development | no data | no data | no data | |
Head of Global Human Resources | 7.3yrs | no data | no data | |
Head of Project Management & Preclinical Development | 6.3yrs | no data | no data | |
Head of Global Quality Management | 1.7yrs | no data | no data | |
Head of Biology | no data | no data | no data |
6.3yrs
Average Tenure
57yo
Average Age
Experienced Management: BSLN's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Non-Executive Director | 7.1yrs | CHF192.13k | 0.0061% CHF 29.8k | |
Independent Non-Executive Director | 2.1yrs | CHF186.88k | no data | |
Independent Chairman of the Board | 12.5yrs | CHF337.68k | 0.0049% CHF 23.9k | |
Independent Non-Executive Director | 11.1yrs | CHF211.75k | 0.015% CHF 71.0k | |
Independent Non-Executive Director | 1.1yrs | CHF192.13k | no data | |
Independent Vice-Chairman | 12.5yrs | CHF224.80k | 0.0099% CHF 48.2k |
9.1yrs
Average Tenure
66yo
Average Age
Experienced Board: BSLN's board of directors are considered experienced (9.1 years average tenure).